Skip to main content
SpringerLink
Log in

Membrane proteins that protect against complement lysis

  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Conclusions

Human cells express a battery of complement regulatory molecules which allow them to survive the continuous low-level complement attack which occurs on all cells exposed to plasma or other biological fluids. An explosion in our knowledge of the structures and mechanisms of action of these regulators has occurred in the last few years as a result of the molecular cloning of all but one (HRF) of the five known inhibitors. The three inhibitors of the C3/C5 convertases are functionally and structurally similar and have arisen from a common ancestor gene. The MAC inhibitors also appear to be functionally similar to each other but structural comparison awaits the cloning of HRF.

The relative importance of these inhibitors is likely to vary between tissues, but in the few instances where this has been studied in detail, CD59 and DAF appear to be the most important in allowing cells to survive complement attack [9,131]. For effective protection it is likely that control is required both at the level of the C3/C5 convertase and at the level of the MAC. Many of the regulatory molecules may subserve other functions which may be equally or more important than their role in control of complement.

The potential clinical applications of these regulatory molecules are just beginning to be realized and will undoubtedly be a major focus of research over the next few years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adams EM, Brown MC, Nunge M, Ng, S-Y, Krych M, Atkinson JP (1991) Contribution of the repeating domains of membrane cofactor protein (MCP; CD46) of the complement system to ligand binding and cofactor activity. J Immunol 147:3005

    PubMed  Google Scholar 

  2. Anderson DJ, Michaelson JS, Johnson PM (1989) Trophoblast/leucocyte common antigen is expressed by human testicular germ cells and appears on the surface of acrosome-reacted sperm. Biol Reprod 41:285

    PubMed  Google Scholar 

  3. Appay MD, Kazatchkine MD, Levi-Strauss M, Hinglais N, Bariety J (1990) Expression of CR1 (CD35) mRNA in podocytes from adult and fetal human kidneys. Kidney Int 38:289

    PubMed  Google Scholar 

  4. Asch AS, Kinoshita T, Jaffe EA, Nussenzweig V (1986) Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med 163:221

    PubMed  Google Scholar 

  5. Ballard L, Seya T, Teckman J, Lublin DM, Atkinson JP (1987) A polymorphism of the complement regulatory protein MCP (membrane cofactor protein or gp45–70). J Immunol 138:3850

    PubMed  Google Scholar 

  6. Berger M, Medof ME (1987) Increased expression of complement decay-accelerating factor during activation of human neutrophils. J Clin Invest 79:214

    PubMed  Google Scholar 

  7. Blaas P, Berger B, Weber S, Peter HH, Hänsch GM (1988) Paroxysmal nocturnal hemoglobinuria: enhanced stimulation of platelets by terminal complement components is related to the lack of C8bp in the membrane. J Immunol 140:3045

    PubMed  Google Scholar 

  8. Bora NS, Lublin DM, Kumar BV, Hockett RD, Holers VM, Atkinson JP (1989) Structural gene for human membrane cofactor protein (MCP) of complement maps to within 100 kb of the 3′ and of the C3b/C4b receptor gene. J Exp Med 169:597

    PubMed  Google Scholar 

  9. Brooimans RA, Vanderark AAJ, Tomita M, Vanes LA, Daha MR (1992) CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis. Eur J Immunol 22:791

    PubMed  Google Scholar 

  10. Campbell RD, Law SKA, Reid KBM, Sim RB (1988) Structure, organization and regulation of the complement genes. Annu Rev Immunol 6:161

    PubMed  Google Scholar 

  11. Caras IW, Davitz MA, Rhee L, Weddell G, Martin DW, Nussenzweig V (1987) Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 325:545

    PubMed  Google Scholar 

  12. Caras IW, Weddell GN, Davitz MA, Nussenzweig V, Martin DW (1987) Signal for attachment of a phospholipid membrane anchor in decay-accelerating factor. Science 238:1280

    PubMed  Google Scholar 

  13. Carroll MC, Alicot EM, Katzman PJ, Klickstein LB, Smith JA, Fearon DT (1987) Organization of the genes encoding complement receptors type 1 and 2, decay accelerating factor and C4-binding protein in the RCA locus on human chromosome 1. J Exp Med 167:1271

    Google Scholar 

  14. Cervoni F, Oglesby TJ, Adams EM, Milesi-Fluet C, Nickells M, Fenichel P, Atkinson JP, Hsi B-L (1992) Identification and characterization of membrane cofactor protein of human spermatozoa. J Immunol 148:1431

    PubMed  Google Scholar 

  15. Cole J, Housley GA, Dykman TR, MacDermott RP, Atkinson JP (1985) Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci USA 83:859

    Google Scholar 

  16. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH (1991) Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation 52:530

    PubMed  Google Scholar 

  17. Dave SJ, Sodetz JM (1990) Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors. J Immunol 144:3087

    PubMed  Google Scholar 

  18. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H (1989) CD59, an Ly-6 like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170:637

    PubMed  Google Scholar 

  19. Davies A, Waldmann H, Morgan BP (1991) Expression of CD59 in insect cells. Complement Inflamm 8:137

    Google Scholar 

  20. Davitz MA, Low MG, Nussenzweig V (1986) Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med 163:1150

    PubMed  Google Scholar 

  21. Deckert M, Kubar J, Bernard A (1992) CD58 and CD59 molecules exhibit potentializing effects in T-cell adhesion and activation J Immunol 148:672

    PubMed  Google Scholar 

  22. Dykman TR, Cole JL, Iida K, Atkinson JP (1983) Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA 80:1698

    PubMed  Google Scholar 

  23. Dykman TR, Hatch JA, Atkinson JP (1984) Polymorphisms of the C3b/C4b receptor (CR1). Identification of a third allelle and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus. J Exp med 159:691

    PubMed  Google Scholar 

  24. Fatima M, Horta M, Ramalhopinto FJ (1991) Role of human decay-accelerating factor inthe evasion of Schistosoma Mansoni from the complement-mediated killing in vitro. J Exp Med 174:1399

    PubMed  Google Scholar 

  25. Fearon DT (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membranes. Proc Natl Acad Sci USA 76:5867

    PubMed  Google Scholar 

  26. Fearon DT (1980) Identification of the membrane glycoprotein that is the C3b-receptor of the human erythrocyte, polymorphonuclear leucocyte, B lymphocyte and monocyte. J Exp Med 15:20

    Google Scholar 

  27. Fearon DT (1984) Cellular receptors for fragments of the third component of complement. Immunol Today 5:105

    Google Scholar 

  28. Fearon DT, Wong WW (1983) Complement ligand-receptor interactions that mediate biological responses. Annu Rev Immunol 1:243

    PubMed  Google Scholar 

  29. Fletcher A, Bryant JA, Gardner B, Judson PA, Spring FA, Parsons SF, Mallinson G, Anstee DJ (1992) New monoclonal antibodies in CD59 — use for the analysis of peripheral blood cells from Paroxysmal Nocturnal Haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology 75:507

    PubMed  Google Scholar 

  30. Forsberg UH, Bazil, V, Stefanova I, Schröder J (1989) Gene for human CD59 (likely Ly-6 homologue) is located on the short arm of chromosome 11. Immunogenetics 30:188

    PubMed  Google Scholar 

  31. Fujita T, Inoue T, Ogawa K, Iida K, Tamura N (1987) The mechanism of action of decay accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 167:1221

    Google Scholar 

  32. Groux H, Huet S, Aubrit F, Cong Tran H, Boumsell L, Bernard A (1989) A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. Comparison of the roles of H19 and LFA-3 molecules in T cell activation. J Immunol 142:3013

    PubMed  Google Scholar 

  33. Hahn WC, Menu E, Bothwell ALM, Sims PJ, Bierer BE (1992) Overlapping but non-identical binding sites on CD2 for CD58 and a second ligand, CD59. Science 256:1805

    PubMed  Google Scholar 

  34. Hamilton KK, Ji Z, Rollins S, Stewart BH, Sims PJ (1990) Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. Blood 76:2572

    PubMed  Google Scholar 

  35. Hänsch GM (1989) The homologous species restriction of the complement attack: structure and function of the C8 binding protein. Curr Top Microbiol Immunol 140:109

    PubMed  Google Scholar 

  36. Hänsch GM, Hammer CH, Vanguri P, Shin ML (1981) Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 78:5118

    PubMed  Google Scholar 

  37. Hänsch GM, Schonermark S, Roelcke D (1987) Paroxysmal nocturnal hemoglobinuria type III; lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J Clin Invest 80:7

    PubMed  Google Scholar 

  38. Hänsch GM, Weller PF, Nicholson-Weller A (1988) Release of C8 binding protein (C8bp) from the cell membrane by phosphatidylinositol-specific phospholipase C. Blood 72:1089

    PubMed  Google Scholar 

  39. Harada R, Okada N, Fujita T, Okada H (1990) Purification of IF5 antigen that prevents complement attack on homologous cell membranes. J Immunol 144:1823

    PubMed  Google Scholar 

  40. Hideshima T, Okada N, Okada H (1990) Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells. Immunology 69:396

    PubMed  Google Scholar 

  41. Hoffmann EM (1969) Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata. Immunochemistry 6:391

    PubMed  Google Scholar 

  42. Hoffmann EM (1969) Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action. Immunochemistry 6:405

    PubMed  Google Scholar 

  43. Hoffmann EM, Etlinger HM (1973) Extraction of complement inhibitory factors from the erythrocytes of non-human species. J Immunol 111:946

    PubMed  Google Scholar 

  44. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ (1989) Isolation andcharacterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84:7

    PubMed  Google Scholar 

  45. Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ (1990) Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood 75:284

    PubMed  Google Scholar 

  46. Holguin MH, Martin CB, Bernshaw NJ, Parker CJ (1992) Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor. J Immunol 148:498

    PubMed  Google Scholar 

  47. Hollander N, Shin ML, Rosse WF, Springer TA (1989) Distinct restriction of complementand cell-mediated lysis. J Immunol 142:3913

    PubMed  Google Scholar 

  48. Holme E, Fyfe A, Zoma A, Veitch J, Hunter J, Whaley K (1985) Decreased C3b receptors (CR1) on erythrocytes from patients with systemic lupus erythematosus. Clin Exp Immunol 62:261

    Google Scholar 

  49. Holmes CH, Simpson KL, Wainwright SD, Tate CG, Houlihan JM, Sawyer IH, Rogers IP, Spring FA, Anstee DJ, Tanner MJ (1990) Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol 144:3099

    PubMed  Google Scholar 

  50. Holmes CH, Simpson KL, Okada H, Okada N, Wainwright SD, Purcell DFJ, Houlihan JM (1992) Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay-accelerating factor (CD55). Eur J Immunol 22:1579

    PubMed  Google Scholar 

  51. Houle JJ, Hoffmann EM, Esser AF (1988) Restriction of cell lysis by homologous complement. II. Protection of erythrocytes against lysis by newly activated complement. Blood 71:287

    PubMed  Google Scholar 

  52. Hourcade D, Meisner DR, Atkinson JP, Holers VM (1988) Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor 1. J Exp Med 168:1255

    PubMed  Google Scholar 

  53. Hourcade D, Holers VM, Atkinson JP (1989) The regulators of complement activation (RCA) gene cluster. Adv Immunol 45:381

    PubMed  Google Scholar 

  54. Hourcade D, Meisner DR, Bee C, Zeldes W, Atkinson JP (1990) Duplication and divergence of the amino-terminal coding region of the complement receptor 1 (CR1) gene. J Biol Chem 265:974

    PubMed  Google Scholar 

  55. Hsi B-L, Hunt JS, Atkinson JP (1991) Differential expression of complement regulatory proteins on subpopulations of human trophoblast cells. J Reprod Immunol 19:209

    PubMed  Google Scholar 

  56. Hughes TR, Piddlesden SJ, Williams JD, Harrison RA, Morgan BP (1992) Isolation and characterisation of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem J 284:169

    PubMed  Google Scholar 

  57. Iida K, Mornaghi R, Nussenzweig V (1982) Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 155:1427

    PubMed  Google Scholar 

  58. Janatova J, Reid KBM, Willis AC (1989) Disulfide bonds are localized within the short concensus repeat units of complement regulatory proteins: C4b-binding protein. Biochemistry 28:4754

    PubMed  Google Scholar 

  59. Jiang S, Persechini PM, Perussia B, Young JD (1989) Resistance of cytoloytic lymphocytes to perforin-mediated killing. Murine cytotoxic T lymphocytes and human natural killer cells do not contain functional soluble homologous restriction factor or other specific soluble protective factors. J Immunol 143:1453

    PubMed  Google Scholar 

  60. Jiang S. Persechini PM, Rosse WF, Perussia B, Young JD (1989b) Differential susceptibility of type III erythrocytes of paroxysmal nocturnal hemoglobinuria to lysis mediated by complement and perform. Biochem Biophys Res Commun 162:316

    Google Scholar 

  61. Kalli K, Hsu P, Bartow TJ, Ahearn JM, Matsumoto AK, Klickstein LB, Fearon DT (1991) Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab′)2 chimeric complement inhibitor. J Exp Med 174:1451

    PubMed  Google Scholar 

  62. Kameyoshi Y, Matsushita M, Okada H (1989) Murine membrane inhibitor of complement which accelerates the decay of human C3 convertase. Immunology 68:439

    PubMed  Google Scholar 

  63. Kinoshita T, Medof ME, Silber R, Nussenzweig V (1985) Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 162:75

    PubMed  Google Scholar 

  64. Kinoshita T, Medof ME, Nussenzweig V (1986) Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes. J Immunol 136:3390

    PubMed  Google Scholar 

  65. Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT (1987) Demonstration of long homologous repeating domains that are composed of the short concensus repeats characteristic of C3b/C4b binding proteins. J Exp Med 165:1095

    PubMed  Google Scholar 

  66. Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT (1988) Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 168:1699

    PubMed  Google Scholar 

  67. Korty PE, Brando C, Shevach EM (1991) CD59 functions as a signal-transducing molecule for human T cell activation. J Immunol 146:4092

    PubMed  Google Scholar 

  68. Krähenbuhl OP, Peter HH, Tschopp J (1989) Absence of homologous restriction factor does not affect CTL-mediated cytolysis. Eur J Immunol 19:217

    PubMed  Google Scholar 

  69. Krych M, Hourcade D, Atkinson JP (1991) Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci USA 88:4353

    PubMed  Google Scholar 

  70. Liszewski MK, Post TW, Atkinson JA (1991) Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 9:431

    PubMed  Google Scholar 

  71. Low MG, Finean JB (1978) Specific release of plasma membrane enzymes by a phosphatidylinositol-specific phospholipase C. Biochim Biophys Acta 508:565

    PubMed  Google Scholar 

  72. Low MG, Saltiel AR (1988) Structural and functional roles of glycosyl-phosphatidylinositol in membranes. Science 239:268

    PubMed  Google Scholar 

  73. Lublin DM, Atkinson JP (1989) Decay-accelerating factor: biochemistry, molecular biology and function. Annu Rev Immunol 7:35

    PubMed  Google Scholar 

  74. Lublin DM, Coyne KE (1991) Phospholipid-anchored and transmembrane forms of either decay accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J Exp Med 174:35

    PubMed  Google Scholar 

  75. Lublin DM, Krsek-Staples J, Pangburn MK, Atkinson JP (1986) Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor. J Immunol 137:1629

    PubMed  Google Scholar 

  76. Lublin DM, Lemons RS, Le Beau MM, Holers VM, Tykocinski M, Medof ME, Atkinson JP (1987) The gene encoding decay-accelerating factor (DAF) is located in the complement regulatory locus on the long arm of chromosome 1. J Exp Med 165:1731

    PubMed  Google Scholar 

  77. Lublin DM, Liszewski MK, Post TW, Arce MA, LeBeau MM, Rebentisch MB, Lemons RS, Seya T, Atkinson JP (1988) Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). J Exp Med 168:181

    PubMed  Google Scholar 

  78. Lutz HU, Stammler P, Fasler S, Ingold M, Fehr J (1992) Density separation of human red blood cells on self-forming Percoll gradients: correlation with cell age. Biochim Biophys Acta 1116:1

    PubMed  Google Scholar 

  79. Malek TR, Ortega G, Chan C, Kroczek RA, Shevach EM (1986) Role of Ly-6 in lymphocyte activation II. Induction of T cell activation by monoclonal anti-Ly-6 antibodies. J Exp Med 164:709

    PubMed  Google Scholar 

  80. Manthei U, Nickells M, Barnes SH, Ballard LL, Cui W, Atkinson JP (1988) Identification of a C3b/iC3 binding protein of rabbit platelets and leucocytes: a CR1-like candidate for the immune adherence molecule. J Immunol 140:1228

    PubMed  Google Scholar 

  81. McGeer PL, Walker DG, Akiyama H, Kawamata T, Guan AL, Parker CJ, Okada N, McGeer EG (1991) Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res 544:315

    PubMed  Google Scholar 

  82. McNearney T, Ballard L, Seya T, Atkinson JP (1989) Membrane cofactor protein of complement is present on human fibroblast, epithelial and endothelial cells. J Clin Invest 84:538

    PubMed  Google Scholar 

  83. Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558

    PubMed  Google Scholar 

  84. Medof ME, Walter EI, Roberts WL, Haas R, Rosenberry TL (1986) Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 25:6740

    PubMed  Google Scholar 

  85. Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Leykam JF, Atkinson JP, Tykocinski ML (1987) Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci USA 84:2007

    PubMed  Google Scholar 

  86. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V (1987) Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165:848

    PubMed  Google Scholar 

  87. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ (1990) Human protectin (CD59), an 18000–20000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1

    PubMed  Google Scholar 

  88. Meri S, Morgan BP, Wing M, Jones J, Davies A, Podack E, Lachmann PJ (1990) Human protectin (CD59), an 18–20-kDa homologous complement restriction factor, does not restrict perforin-mediated lysis. J Exp Med 172:367

    PubMed  Google Scholar 

  89. Meri S, Waldmann H, Lachmann PJ (1991) Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65:532

    PubMed  Google Scholar 

  90. Meri S, Väkevä A, Laari T, Lachmann PJ (1991) Soluble forms of CD59 antigen: distribution in body fluids and functional activity. Complement Inflamm 8:193

    Google Scholar 

  91. Meri S, Mattila P, Renkonen R (1993) Regulating of CD59 expression on the human endothelial cell line E.A.hy. 926. Eur J Immunol (in press)

  92. Merry AH, Rawlinson VI, Uchikawa M, Daha MR, Sim RB (1989) Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Br J Haematol 73:248

    PubMed  Google Scholar 

  93. Miyakawa Y, Yamada A, Kosaka K, Tsuda K, Tsuda F, Kosugi E, Mayumi M (1981) Defective immune adherence receptor (C3b) on erythrocytes from patients with systemic lupus erythematosus. Lancet II:493

    Google Scholar 

  94. Moldenhauer F, David J, Fielder AHL, Lachmann PJ, Walport MJ (1987) Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus. Arthritis Rheum 30:961

    PubMed  Google Scholar 

  95. Moran P, Caras IW (1991) Fusion of sequence elements from non-anchored proteins to generate a fully functional signal for glycophosphatidylinositol membrane anchor attachment. J Cell Biol 115:1595

    PubMed  Google Scholar 

  96. Morgan BP (1989) Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 264:1

    PubMed  Google Scholar 

  97. Morgan BP (1992) Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol 178:115

    PubMed  Google Scholar 

  98. Morgan BP (1992) Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes. Biochem J 282:409

    PubMed  Google Scholar 

  99. Muir R (1911) On the relationships between the complement and the immune bodies of different animals. J Pathol Bacteriol 16:523

    Google Scholar 

  100. Nicholson-Weller A, Burge J, Austen KF (1981) Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical C4 convertase, C4b,2a. J Immunol 127:2035

    PubMed  Google Scholar 

  101. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184

    PubMed  Google Scholar 

  102. Nicholson-Weller A, March, JP, Rosenfeld SI, Austen KF (1983) Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein decay-accelerating factor. Proc Natl Acad Sci USA 80:5066

    PubMed  Google Scholar 

  103. Nicholson-Weller A, Spicer DB, Austen KF (1985) Deficiency of the complement regulatory protein, “decay-accelerating factor”, on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med 312:1091

    PubMed  Google Scholar 

  104. Nicholson-Weller A, Russian DA, Austen KF (1986) Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay-accelerating factor (DAF). J Immunol 137:1275

    PubMed  Google Scholar 

  105. Nickels MW, Atkinson JP (1990) Characterization of CR1 and membrane cofactor protein-like proteins of two primates. J Immunol 144:4262

    PubMed  Google Scholar 

  106. Nikaido TA, Shimizu A, Ishida N, Histaka S, Teshigawara K, Maeda M, Uchiyama T, Yodoi J, Honjo T (1984) Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature 311:631

    PubMed  Google Scholar 

  107. Ninomiya H, Stewart BH, Rollins SA, Zhao J, Bothwell ALM, Sims PJ (1992) Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity. J Biol Chem 267:8404

    PubMed  Google Scholar 

  108. Ninomiya H, Chang C-P, Stewart BH, Sims PJ (1992) Specific binding of complement inhibitor CD59 to C8alpha and to the b domain of C9. FASEB J 6: A1450

    Google Scholar 

  109. Noda K, Nakano Y, Tobe T, Choi-Mura N, Tomita M, Endo T, Kobata A (1991) Characterization of a glycosylphosphatidylinositol anchor and an N-glycosidic oligosaccharide chain of MACIF (CD59). Complement Inflamm 8:199

    Google Scholar 

  110. Nose M, Katoh M, Okada N, Kyogoku M, Okada H (1990) Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 70:145

    PubMed  Google Scholar 

  111. Oglesby TJ, Allen CJ, Liszewski MK, White DJG, Atkinson JP (1992) Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 175:1547

    PubMed  Google Scholar 

  112. Okada H, Nagami Y, Takahashi K, Okada N, Hideshima T, Takizawa H, Kondo J (1989) 20 kDa homologous restriction factor of complement resembles T cell activating protein. Biochem Biophys Res Commun 162:1553

    PubMed  Google Scholar 

  113. Okada N, Harada R, Fujita T, Okada H (1989) A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1:205

    PubMed  Google Scholar 

  114. Okada N, Harada R, Okada H (1990) Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor. Clin Exp Immunol 80:109

    PubMed  Google Scholar 

  115. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1983) Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 80:5430

    PubMed  Google Scholar 

  116. Pearce EJ, Hall BF, Sher A (1990) Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling decay accelerating factor. J Immunol 144:2751

    PubMed  Google Scholar 

  117. Petranka JG, Fleenor DE, Sykes K, Kaufman RA, Rosse WF (1991) The structure of the CD59 gene. Complement Inflamm 8:209

    Google Scholar 

  118. Philbrick WM, Palfree RG, Maher SE, Bridgett MM, Sirlin S, Bothwell AL (1990) The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility. Eur J Immunol 20:87

    PubMed  Google Scholar 

  119. Post TW, Arce MA, Liszewski MK, Thompson ES, Atkinson JA, Lublin DM (1990) Structure of the gene for human complement protein decay accelerating factor. J Immunol 144:740

    PubMed  Google Scholar 

  120. Post TW, Liszewski MK, Adams EM, Tedja I, Miller EA, Atkinson JP (1991) Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/prolinerich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J Exp Med 174:93

    PubMed  Google Scholar 

  121. Purcell DFJ, McKenzie IFC, Lublin DM, Johnson PM, Atkinson JP, Oglesby TJ, Deacon NJ (1990) The human cell surface glycoproteins HuLy-m5, membrane cofactor protein (MCP) of the complement system and trophoblast-leucocyte common (TLX) antigen are CD46. Immunology 70:155

    PubMed  Google Scholar 

  122. Purcell DFJ, Russell SM, Deacon NJ, Brown MA, Hooker DJI, McKenzie IFC (1991) Alternatively spliced RNAs encode several isoforms of CD46 (MCP), a regulator of complement activation. Immunogenetics 33:335

    PubMed  Google Scholar 

  123. Ratnoff WD, Knez JJ, Prince GM, Okada H, Lachmann PJ, Medof ME (1992) Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin Exp Immunol 87:415

    PubMed  Google Scholar 

  124. Reiter Y, Ciobotarin A, Fishelson Z (1992) Sublytic complement attack protects tumorcells from lytic doses of antibody and complement. Eur J Immunol 22:1207

    PubMed  Google Scholar 

  125. Rey-Campos J, Rubinstein P, De Cordoba SR (1987) Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans. J Exp Med 166:246

    PubMed  Google Scholar 

  126. Reynes M, Aubert JP, Cohen JH, Audouin J, Trittet V, Diebold J, Kazatchkine MD (1985) Human follicular dendritic cells express CR1, CR2 and CR3 complement receptor antigens. J Immunol 135:2887

    PubMed  Google Scholar 

  127. Ripoche J, Sims RB (1986) Loss of complement receptor type 1 (CR1) on ageing of erythrocytes. Biochem J 235:815

    PubMed  Google Scholar 

  128. Rodriguez de Cordoba S, Lublin DM, Rubinstein P, Atkinson JP (1985) Human genes for three complement components that regulate the activation of C3 are tightly linked. J Exp Med 161:1189

    PubMed  Google Scholar 

  129. Rollins SA, Sims, PJ (1990) The complement inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144:3478

    PubMed  Google Scholar 

  130. Rollins SA, Zhao J, Ninomiya H, Sims PJ (1991) Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 146:2345

    PubMed  Google Scholar 

  131. Rooney IA, Morgan BP (1990) Protection of human amniotic epithelial cells (HAEC) from complement-mediated lysis: expression on the cells of three complement inhibitory membrane proteins. Immunology 71:308

    PubMed  Google Scholar 

  132. Rooney IA, Morgan BP (1992) Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 76:541

    PubMed  Google Scholar 

  133. Rooney IA, Davies A, Williams JD, Griffiths D, Meri S, Lachmann PJ, Morgan BP (1991) The complement inhibiting protein protectin (CD59 antigen) is present and functionally active on glomerular epithelial cells. Clin Exp Immunol 83:251

    PubMed  Google Scholar 

  134. Rooney IA, Davies A, Morgan BP (1992) Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC-inhibitory proteins. Immunology 75:499

    PubMed  Google Scholar 

  135. Rooney IA, Atkinson JP, Krul ES, Sconfeld G, Polakoski K, Saffitz JE, Morgan BP (1993) Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma. J Exp Med 177:1409

    PubMed  Google Scholar 

  136. Rosse W (1990) Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 75:1595

    PubMed  Google Scholar 

  137. Rosse WF, Adams JP, Thorpe AM (1974) The population of cells in paroxysmal nocturnal hemoglobinuria of intermediate sensitivity to complement lysis. Br J Haematol 28:181

    PubMed  Google Scholar 

  138. Sawada R, Ohashi K, Okano K, Hattori M, Minato N, Naruto M (1989) Complementary DNA sequence and deduced peptide sequence for CD59/MEM-43 antigen, the human homologue of murine lymphocyte antigen Ly-6C. Nucleic Acids Res 17:6728

    PubMed  Google Scholar 

  139. Sawada R, Ohashi K, Anaguchi H, Okazaki H, Hattori M, Minato N, Naruto M (1990) Isolation and expression of the full-length cDNA encoding CD59 antigen of human lymphocytes. DNA Cell Biol 9:213

    PubMed  Google Scholar 

  140. Sayama K, Shiraishi S, Shirakata Y, Kobayashi Y, Okada N, Okada H, Miki Y (1990) Characterization of homologous restriction factor (HRF20) in human skin and leucocytes. Clin Exp Immunol 82:355

    PubMed  Google Scholar 

  141. Schieren G, Janssen O, Hänsch GM (1992) Enhanced expression of the complement regulatory factor C8-binding protein (C8bp) on U937 cells after stimulation with IL-1β, endotoxin, IFN or phorbol ester. J Immunol 148:3183

    PubMed  Google Scholar 

  142. Schifferli JA, Ng YC, Peters DK (1986) The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 315:488

    PubMed  Google Scholar 

  143. Schifferli JA, Ng YC, Pascaud J-P, Walport MJ (1989) The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearence in humans. Clin Exp Immunol 75:329

    PubMed  Google Scholar 

  144. Schönermark S, Rauterberg EW, Shin ML, Loke S, Roelcke D, Hänsch GM (1986) Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136:1772

    PubMed  Google Scholar 

  145. Schönermark S, Felsinger S, Berger B, Hänsch GM (1988) The C8-binding protein of human erythrocytes: interaction with the components of the complement attack phase. Immunology 63:585

    PubMed  Google Scholar 

  146. Schönermark S, Hess S, Berger B, Rother K, Hänsch GM (1992) Complement regulatory proteins in glomerular cells. Kidney Int 37:431

    Google Scholar 

  147. Seya T, Atkinson JP (1989) Functional properties of membrane cofactor protein of complement. Biochem J 264:581

    PubMed  Google Scholar 

  148. Seya T, Turner J, Atkinson JP (1986) Purification and characterization of a membrane protein (gp45–70) which is a cofactor for cleavage of C3b and C4b. J Exp Med 163:837

    PubMed  Google Scholar 

  149. Seya T, Ballard L, Bora N, McNearney T, Atkinson JP (1988) Distribution of membrane cofactor protein (MCP) of complement on human peripheral blood cells. Eur J Immunol 18:1289

    PubMed  Google Scholar 

  150. Shibata T, Cosio FG, Birmingham DJ (1991) Complement activation induces the expression of decay accelerating factor on human mesangial cells. J Immunol 147:3901

    PubMed  Google Scholar 

  151. Shin ML, Hänsch G, Hu VW, Nicholson-Weller A (1986) Membrane factors responsible for homologous restriction of complement-mediated lysis: evidence of a factor other than DAF operating at the stage of C8 and C9. J Immunol 136:1777

    PubMed  Google Scholar 

  152. Sims PJ, Rollins SA, Weidmer T (1989) Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J Biol Chem 264:19228

    PubMed  Google Scholar 

  153. Stafford HA, Tykocinski ML, Lublin DM, Holers VM, Rosse WF, Atkinson JP, Medof ME (1988) Normal polymorphic variations and transcription of the decay-accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci USA 85:880

    PubMed  Google Scholar 

  154. Stefanova I, Horejsi V (1991) Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. J Immunol 147:1587

    PubMed  Google Scholar 

  155. Stefanova I, Hilgert I, Kristofova H, Brown R, Low MG, Horejsi J (1989) Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol Immunol 26:153

    PubMed  Google Scholar 

  156. Stern PL, Beresford N, Thompson S, Johnson PM, Webb PD, Hole N (1986) Characterization of the human trophoblast-leucocyte antigenic molecules defined by a monoclonal antibody. J Immunol 137:1604

    PubMed  Google Scholar 

  157. Su B, Wanek GL, Flavell RA, Bothwell ALM (1991) The glycosyl phosphatidylinositol anchor is critical for Ly-6A/E-mediated T cell activation. J Cell Biol 112:377

    PubMed  Google Scholar 

  158. Sugita Y, Uzawa M, Tomita M (1987) Isolation of a decay-accelerating factor from rabbit erythrocyte membranes. J Immunol Methods 104:123

    PubMed  Google Scholar 

  159. Sugita Y, Nakano Y, Tomita M (1988) Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 104:633

    PubMed  Google Scholar 

  160. Sugita Y, Mazda T, Tomita M (1989) Amino terminal amino acid sequence and chemical and functional properties of a membrane attack complex inhibiting factor from human erythrocytes. J Biochem 106:589

    PubMed  Google Scholar 

  161. Sugita Y, Tobe T, Oda E, Tomita M, Yasukawa K, Yamaji N, Takemoto T, Furuichi K, Takayama M, Yano S (1989) Molecular cloning and characterisation of MACIF, an inhibitor of membrane channel formation of complement. J Biochem 106:555

    PubMed  Google Scholar 

  162. Tandon N, Morgan BP, Weetman AP (1992) Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells. Immunology 75:372

    PubMed  Google Scholar 

  163. Tate CG, Uchikawa M, Tanner MJA, Judson PA, Parsons SF, Mallinson G, Anstee DJ (1989) Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype. Biochem J 261:489

    PubMed  Google Scholar 

  164. Telen MJ, Green AM (1989) The Inab phenotype: Characterization of the membrane protein and complement regulatory defect. Blood 74:437

    PubMed  Google Scholar 

  165. Telen MJ, Hall SE, Green AM, Moulds JJ, Rosse WF (1988) Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 167:1993

    PubMed  Google Scholar 

  166. Thomas J, Webb W, Davitz MA, Nussenzweig V (1987) Decay accelerating factor diffuses rapidly on HeLa surfaces. Biophys J 51:522

    Google Scholar 

  167. Tykocinski ML, Shu HK, Ayers DJ, Walter EI, Getty RR, Groger RK, Hauer CA, Medof ME (1988) Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3′ end sequence of decay-accelerating factor's mRNA. Proc Natl Acad Sci USA 85:3555

    PubMed  Google Scholar 

  168. van den Berg CW, Morgan BP (1993) The sheep analogue of human CD59: purification and characterisation as a species non-selective inhibitor of complement. Immunology 78:349

    PubMed  Google Scholar 

  169. Väkevä A, Laurila P, Meri S (1993) Loss of expression of protectin (CD59) associates with complement membrane attack complex deposition in myocardial infarction. Lab Invest 67:608

    Google Scholar 

  170. Vedeler CA, Matre R (1990) Peripheral nerve CR1 expresses in situ cofactor activity for degradation of C3b. J Neuroimmunol 26:51

    PubMed  Google Scholar 

  171. Walter EI, Roberts WL, Rosenberry TL, Ratnoff WD, Medof ME (1990) Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositolspecific phospholipase C cleavage. J Immunol 144:1030

    PubMed  Google Scholar 

  172. Walter EI, Ratnoff WD, Long KE, Kazura JW, Medof ME (1992) Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accelerating factor protein in cells. J Biol Chem 267:1245

    PubMed  Google Scholar 

  173. Watts MJ, Patel AK, Morgan BP (1987) C9-binding protein: purification, characterization and reincorporation into lipid vesicles. Complement 4:236

    Google Scholar 

  174. Watts MJ, Dankert JR, Morgan BP (1990) Isolation and characterization of a membrane attack complex inhibiting protein present in human serum and other biological fluids. Biochem J 265:471

    PubMed  Google Scholar 

  175. White DJG (1992) Transplantation of organs between species. Int Arch Allergy Appl Immunol 98:1

    Google Scholar 

  176. Whitlow MB, Iida K, Stefanova I, Bernard A, Nussenzweig V (1990) H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol 126:176

    PubMed  Google Scholar 

  177. Wilcox LA, Ezzell JL, Bernshaw NJ, Parker CJ (1991) Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. Blood 78:820

    PubMed  Google Scholar 

  178. Wilson JG, Wong WW, Schur PH and Fearon DT (1982) Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 307:981

    PubMed  Google Scholar 

  179. Wong WW (1990) Structural and functional correlation of the human complement receptor type 1. J Invest Dermatol 94:64s-67s

    PubMed  Google Scholar 

  180. Wong WW, Wilson JG, Fearon DT (1983) Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest 72:685

    PubMed  Google Scholar 

  181. Wong WW, Cahill JM, Rosen MD, Kennedy CA, Bonaccio ET, Morris MJ, Wilson JD, Klickstein LB, Fearon DT (1989) Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J Exp Med 169:847

    PubMed  Google Scholar 

  182. Yamamoto H, Blaas P, Nicholson-Weller A, Hänsch GM (1990) Homologous species restriction of the complement-mediated killing of nucleated cells. Immunology 70:422

    PubMed  Google Scholar 

  183. Yamamoto K-I (1977) Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8 dependent variation in lytic activity. J Immunol 119:1482

    PubMed  Google Scholar 

  184. Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, Russell DW (1984) The human LDL receptor: a cystein-rich protein with multiple Alu sequences in its mRNA. Cell 39:27

    PubMed  Google Scholar 

  185. Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Norii T, Okada N, Okada H, Inoue K, Kitani T (1990) Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 323:1184

    PubMed  Google Scholar 

  186. Yoon SH, Fearon DT (1985) Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol 134:2332

    Google Scholar 

  187. Young JDE, Jiang S, Liu CC, Hasselkus-Light CS (1990) Anti-idiotypic antibodies derived against C8, C9 and perform bind homologous restriction factor. J Immunol Methods 128:133

    PubMed  Google Scholar 

  188. Young JDE, Rosse WF, Hasselkus-Light CS (1990) The homologous restriction factor is immunologically related to complement components C8 and C9 and to lymphocyte poreforming protein perforin through cysteine-rich domains. Biochem Biophys Res Commun 166:648

    PubMed  Google Scholar 

  189. Yu G, Holers VM, Seya T, Ballard L, Atkinson JP (1986) Identification of a third component of complement-binding glycoprotein of human platelets. J Clin Invest 78:494

    PubMed  Google Scholar 

  190. Zalman LS, Wood LM, Müller-Eberhard HJ (1986) Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 83:6975

    PubMed  Google Scholar 

  191. Zalman LS, Wood LM, Frank MM, Müller-Eberhard HJ (1987) Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J Exp Med 165:572

    PubMed  Google Scholar 

  192. Zalman LS, Wood LM, Müller-Eberhard HJ (1987) Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes. J Exp Med 166:947

    PubMed  Google Scholar 

  193. Zalman LS, Brothers MA, Müller-Eberhard HJ (1988) Self-protection of cytotoxic lymphocytes by a soluble form of homologous restriction factor in cytoplasmic granules. Proc Natl Acad Sci USA 85:4827

    PubMed  Google Scholar 

  194. Zalman LS, Brothers MA, Müller-Eberhard HJ (1989) Isolation of homologous restriction factor from human urine. Immunochemical properties and biologic activity. J Immunol 143:1943

    PubMed  Google Scholar 

  195. Zalman LS, Brothers MA, Strauss KL (1991) Inhibition of cytolytic lymphocytes by homologous restriction factor. Lack of species restriction. J Immunol 146:4278

    PubMed  Google Scholar 

  196. Zhao J, Rollins SA, Maher SE, Bothwell AL, Sims PJ (1991) Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J Biol Chem 266:13418

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biochemistry, University of Wales College of Medicine, CF4 4XN, Heath Park, Cardiff, UK

    B. Paul Morgan

  2. Department of Bacteriology and Immunology, University of Helsinki, FIN-00014, Helsinki, Finland

    Seppo Meri

Authors
  1. B. Paul Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seppo Meri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morgan, B.P., Meri, S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 15, 369–396 (1994). https://doi.org/10.1007/BF01837366

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01837366

Keywords

Search

Navigation